Grant: Strategic Projects - Group
University of Toronto
$121,250.00
Engineering vascular networks by site specific differentiation of angiogenic progenitor cells
FY 2009-10
Summary
Tissue engineering may offer alternative treatment options for organ replacement but challenges related to the functional vascularization, rapid connection to the host vasculature and survival of cells in complex thick tissues remain. We propose here a strategy based on photolithography and site specific differentiation of bipotent angiogenic progenitor cells (APC) to engineering a prototype 3D vascular network consisting of 2 branching vessels. We will use APCs derived from mouse embryonic stem cells for method development, followed by the use ofAPCs derived from human peripheral blood. In our preliminary studies, we covalently immobilized vascular endothelial growth factor (VEOF) or platelet derived growth factor (POOF) on collagen IV. APCs preferentially differentiated into endothelial cells (ECs) with immobilized VEOF; vascular smooth
muscle cells (VSMC) were preferentially obtained with immobilized POOF. In Aiml we will further optimize this differentiation in 20 micropatterned culture, by increasing the amounts of immobilized growth factors and applying shear flow (for improved EC phenotype). In Aim2, we will assemble a 3D branching vessel using layer-by-layer photocrosslinking of chitosan, as investigated in preliminary studies. The spacing between the branching vessels will be varied from 400microm to 2mm. We will coat the lumen with VEOF-collagen IV, while the exterior will be coated with POOF-collagen IV. Upon seeding and cultivation of APCs in perfusion, the cells in the lumen of the branching vessels will tum into ECs, while those on its exterior surface will tum into VSMCs. In Aim 3, we will assess the hemocompatibility of this vascular network in vitro using human
and mouse blood. Our industrial partner is an emerging biomedical company, Rimon Therapeutics. This proposal will set a new paradigm for tissue engineering of vascular networks by controlling geometry and surface chemistry of hotocrosslinkable hydrogels, while starting from progenitors harvested from patient's blood in a non-invasive manner.
Program
Strategic Projects - Group
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
381002-2009
Name nom
Radisic, Milica
Department département
Chemical Engineering and Applied Chemistry
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2009
Competition year année de concours
2009
Award amount
121250
Program id
STPGP
Program nane en
Strategic Projects - Group
Program name fr
Projets stratégiques - De groupe
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1042
Committee name en
Strategic Projects Selection Panel - Biomedical Technologies
Committee name fr
Comité de sélection des projets stratégiques - Technologies biomédicales
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Partie
1
Nb partie
3
Application title
Engineering vascular networks by site specific differentiation of angiogenic progenitor cells
Keyword
NA
Application summary
Tissue engineering may offer alternative treatment options for organ replacement but challenges related to the functional vascularization, rapid connection to the host vasculature and survival of cells in complex thick tissues remain. We propose here a strategy based on photolithography and site specific differentiation of bipotent angiogenic progenitor cells (APC) to engineering a prototype 3D vascular network consisting of 2 branching vessels. We will use APCs derived from mouse embryonic stem cells for method development, followed by the use ofAPCs derived from human peripheral blood. In our preliminary studies, we covalently immobilized vascular endothelial growth factor (VEOF) or platelet derived growth factor (POOF) on collagen IV. APCs preferentially differentiated into endothelial cells (ECs) with immobilized VEOF; vascular smooth
muscle cells (VSMC) were preferentially obtained with immobilized POOF. In Aiml we will further optimize this differentiation in 20 micropatterned culture, by increasing the amounts of immobilized growth factors and applying shear flow (for improved EC phenotype). In Aim2, we will assemble a 3D branching vessel using layer-by-layer photocrosslinking of chitosan, as investigated in preliminary studies. The spacing between the branching vessels will be varied from 400microm to 2mm. We will coat the lumen with VEOF-collagen IV, while the exterior will be coated with POOF-collagen IV. Upon seeding and cultivation of APCs in perfusion, the cells in the lumen of the branching vessels will tum into ECs, while those on its exterior surface will tum into VSMCs. In Aim 3, we will assess the hemocompatibility of this vascular network in vitro using human
and mouse blood. Our industrial partner is an emerging biomedical company, Rimon Therapeutics. This proposal will set a new paradigm for tissue engineering of vascular networks by controlling geometry and surface chemistry of hotocrosslinkable hydrogels, while starting from progenitors harvested from patient's blood in a non-invasive manner.